Trial Profile

An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Ciclosporin; Gold; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms EXTRA
Sponsors Pfizer; Wyeth

05 Oct 2021 This trial has been completed in Spain and France (End Date: 27 Jan 2010), according to European Clinical Trials Database record.
10 Mar 2012 The trial status is recruiting in (Spain, France, United Kingdom), completed in (Denmark) as reported by European Clinical Trials Database.
20 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com